Molecular pharmacology of second-generation antihistamines

Histamine was the first allergic mediator identified in the early part of this century. it has three defined receptors, but most effects of histamine in allergic reactions are through the HI receptor The first HI antagonists were introduced into clinical use in the late 1940s, and drugs of this class are still the preferred initial choice for management of allergic rhinitis and uuricnrin. The first-generation drugs were characterized by nonspecific binding to many receptors and penetration of the blood-brain barrier resulting in multiple sine effects. Within the central nervous system (CNS), interference with normal histamine binding to the HI receptor is associated with drowsiness and psychomotor impairment. The second-generation drugs have a much improved benefit/adverse effect profile, largely based on greater potency, receptor specificity and lower CNS penetration The potency of antihistamines for blocking HI receptors can be compared by their inhibition of the cutaneous wheal and flare response to histamine. These drugs seem to have additional antiallergic properties related to blockade of mediator release and interference with cellular recruitment and activation. Clinical trials comparing the efficacy of antihistamines in rhinitis and asthma are reviewed Recent studies have explored the potential of antihistamines to prevent the progression of allergy and their enhanced efficacy when combined with leukotriene antagonists.